CompareMarketResearchRequest a sample
Home / Healthcare / Biologics

Healthcare · Market report

Biologics Market Size, Share and Forecast 2026-2036

The global biologics market is worth USD 508 bn in 2026 and is forecast to reach USD 1.1 tn by 2036, growing at a 8.0% CAGR. United States is the largest country market and Monoclonal antibodies is the largest by product segment.

USD 508 bnMarket size 2026
USD 1.1 tnForecast 2036
8.0%CAGR 2026-2036
United StatesLargest country

Request a free sample Jump to the forecast

Report price: Starts from USD 1,999

5 segmentation views25 countries2026 to 2036 yearly forecast

Market overview

The global biologics market is worth USD 508 bn in 2026 and is forecast to reach USD 1.1 tn by 2036, growing at a 8.0% CAGR. United States is the largest country market and Monoclonal antibodies is the largest by product segment.

ScopeMedicines made from living cells that are proteins, antibodies, hormones, enzymes and similar products, including monoclonal antibodies, insulins, fusion proteins and blood-derived products, sold worldwide.
IndustryHealthcare
Value 2025USD 470 bn
Value 2026USD 508 bn
Value 2036USD 1.1 tn
CAGR 2026-20368.0%
Volume 20262,673 million units
Volume 20365,225 million units
Average price 2026USD 190 per unit
Report priceStarts from USD 1,999
PublishedNovember 2026

Request a free sample of this report

Biologics market size and forecast, 2026-2036

Exhibit 1The global biologics market is forecast to grow from USD 508 bn in 2026 to USD 1.1 tn by 2036, more than doublingGlobal market value in USD: 2025 base year, 2026 estimate and forecast to 2036. CAGR 2026 to 2036: 8.0%
Biologics market value, 2025 to 2036Market value by year. 2025: USD 470 bn; 2026: USD 508 bn; 2027: USD 548 bn; 2028: USD 592 bn; 2029: USD 639 bn; 2030: USD 691 bn; 2031: USD 746 bn; 2032: USD 805 bn; 2033: USD 870 bn; 2034: USD 940 bn; 2035: USD 1.0 tn; 2036: USD 1.1 tn. Compound annual growth rate 2026 to 2036: 8.0%.2025508 bn2026746 bn20311.1 tn20368.0% CAGR

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

YearMarket value
2026USD 508 bn
2027USD 548 bn
2028USD 592 bn
2029USD 639 bn
2030USD 691 bn
2031USD 746 bn
2032USD 805 bn
2033USD 870 bn
2034USD 940 bn
2035USD 1.0 tn
2036USD 1.1 tn

Biologics market segmentation

By product

Exhibit 2Monoclonal antibodies is the largest segment by product, with 55.0% of 2026 revenueEstimated share of 2026 global revenue, by product
Biologics market share by product, 2026Share of 2026 revenue by product. Monoclonal antibodies: 55.0%; Insulins and hormones: 12.0%; Fusion proteins and enzymes: 10.0%; Blood and plasma products: 9.0%; Antibody-drug conjugates and bispecifics: 8.0%; Others: 6.0%.Monoclonal antibodies55.0%Insulins and hormones12.0%Fusion proteins and enzymes10.0%Blood and plasma products9.0%Antibody-drug conjugates and bispecifics8.0%Others6.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Monoclonal antibodies55.0%54.4%USD 279 bn7.9%
Insulins and hormones12.0%9.4%USD 60.9 bn5.4%
Fusion proteins and enzymes10.0%8.6%USD 50.8 bn6.4%
Blood and plasma products9.0%7.4%USD 45.7 bn5.9%
Antibody-drug conjugates and bispecifics8.0%15.4%USD 40.6 bn15.3%
Others6.0%4.7%USD 30.5 bn5.4%

By therapy area

Exhibit 3Oncology adds the most revenue by therapy area, growing from USD 178 bn in 2026 to USD 456 bn by 2036Estimated revenue in USD by therapy area, 2026 and 2036 forecast
Biologics market by therapy area, 2026 and 2036Revenue by therapy area in 2026 and 2036. Oncology: USD 178 bn in 2026, USD 456 bn in 2036, change +157%; Immunology: USD 137 bn in 2026, USD 255 bn in 2036, change +86%; Other: USD 81.2 bn in 2026, USD 151 bn in 2036, change +86%; Diabetes and metabolic: USD 60.9 bn in 2026, USD 130 bn in 2036, change +114%; Hematology and rare disease: USD 50.8 bn in 2026, USD 104 bn in 2036, change +104%.20262036 forecastChangeOncology+157%178 bn456 bnImmunology+86%137 bn255 bnOther+86%81.2 bn151 bnDiabetes and metabolic+114%60.9 bn130 bnHematology and rare disease+104%50.8 bn104 bn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Oncology35.0%41.6%USD 178 bn9.9%
Immunology27.0%23.2%USD 137 bn6.4%
Diabetes and metabolic12.0%11.9%USD 60.9 bn7.9%
Hematology and rare disease10.0%9.5%USD 50.8 bn7.4%
Other16.0%13.8%USD 81.2 bn6.4%

By molecule type

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Monoclonal antibodies46.0%46.0%USD 233 bn8.0%
Recombinant proteins20.0%18.0%USD 102 bn6.9%
Vaccines14.0%13.0%USD 71.1 bn7.2%
Cell and gene therapies6.0%10.0%USD 30.5 bn13.7%
Fusion proteins and others14.0%13.0%USD 71.1 bn7.2%

By manufacturing source

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Mammalian cell lines62.0%60.0%USD 315 bn7.7%
Microbial18.0%16.0%USD 91.4 bn6.7%
Plasma derived12.0%12.0%USD 60.9 bn8.0%
Transgenic and others8.0%12.0%USD 40.6 bn12.5%

By route of administration

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Intravenous42.0%38.0%USD 213 bn6.9%
Subcutaneous38.0%43.0%USD 193 bn9.3%
Intramuscular and other20.0%19.0%USD 102 bn7.5%

Top 25 countries for biologics by revenue

Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 86.1% of 2026 revenue and the 25 countries below together hold 95.5%.

Exhibit 4United States is the largest country market at USD 264 bn in 2026, and the three largest countries hold 64.0% of global revenueEstimated 2026 revenue in USD and share of the global market, ten largest countries
Biologics market, ten largest countries in 2026Ten largest countries by 2026 revenue. United States: USD 264 bn, 52.0%; Germany: USD 30.5 bn, 6.0%; Japan: USD 30.5 bn, 6.0%; China: USD 30.5 bn, 6.0%; France: USD 17.8 bn, 3.5%; United Kingdom: USD 15.2 bn, 3.0%; Italy: USD 14.2 bn, 2.8%; Spain: USD 12.2 bn, 2.4%; Canada: USD 12.2 bn, 2.4%; Brazil: USD 10.2 bn, 2.0%.United States264 bn 52.0%Germany30.5 bn 6.0%Japan30.5 bn 6.0%China30.5 bn 6.0%France17.8 bn 3.5%United Kingdom15.2 bn 3.0%Italy14.2 bn 2.8%Spain12.2 bn 2.4%Canada12.2 bn 2.4%Brazil10.2 bn 2.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

#CountryValue 2026Share 2026Value 2036CAGR 2026-36
1United StatesUSD 264 bn52.0%USD 573 bn8.1%
2GermanyUSD 30.5 bn6.0%USD 60.3 bn7.1%
3JapanUSD 30.5 bn6.0%USD 52.6 bn5.6%
4ChinaUSD 30.5 bn6.0%USD 95.3 bn12.1%
5FranceUSD 17.8 bn3.5%USD 34.0 bn6.7%
6United KingdomUSD 15.2 bn3.0%USD 29.6 bn6.9%
7ItalyUSD 14.2 bn2.8%USD 26.3 bn6.3%
8SpainUSD 12.2 bn2.4%USD 23.0 bn6.6%
9CanadaUSD 12.2 bn2.4%USD 24.1 bn7.1%
10BrazilUSD 10.2 bn2.0%USD 24.1 bn9.0%
11SwitzerlandUSD 8.9 bn1.8%USD 19.2 bn7.9%
12BelgiumUSD 6.9 bn1.4%USD 14.7 bn7.9%
13NetherlandsUSD 6.1 bn1.2%USD 13.3 bn8.0%
14IrelandUSD 5.5 bn1.1%USD 11.8 bn8.0%
15South KoreaUSD 3.9 bn0.8%USD 9.4 bn9.2%
16IndiaUSD 3.0 bn0.6%USD 7.2 bn9.2%
17AustraliaUSD 2.9 bn0.6%USD 6.2 bn8.0%
18SwedenUSD 2.6 bn0.5%USD 5.6 bn8.0%
19DenmarkUSD 2.2 bn0.4%USD 4.6 bn7.8%
20AustriaUSD 1.5 bn0.3%USD 3.3 bn8.0%
21MexicoUSD 1.2 bn0.2%USD 2.8 bn9.3%
22Saudi ArabiaUSD 964 mn0.2%USD 2.3 bn9.1%
23PolandUSD 812 mn0.2%USD 2.0 bn9.3%
24IsraelUSD 812 mn0.2%USD 1.8 bn8.0%
25SingaporeUSD 711 mn0.1%USD 1.8 bn9.4%
Rest of worldUSD 22.6 bn4.5%USD 47.5 bn7.7%
Exhibit 5United States and China account for 64% of the USD 588 bn the market is forecast to add by 2036Forecast revenue added between 2026 and 2036 by country, in USD
Biologics market, where the growth to 2036 comes fromRevenue added between 2026 and 2036. Market value 2026: USD 508 bn. United States: +USD 309 bn; China: +USD 64.9 bn; Germany: +USD 29.8 bn; Japan: +USD 22.1 bn; France: +USD 16.2 bn; 20 other countries: +USD 121 bn; Rest of world: +USD 24.9 bn. Market value 2036: USD 1.1 tn.Market value 2026508 bnUnited States+309 bnChina+64.9 bnGermany+29.8 bnJapan+22.1 bnFrance+16.2 bn20 other countries+121 bnRest of world+24.9 bnMarket value 20361.1 tn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

Competitive landscape

Group 1: Global leaders

  • Roche
  • Merck
  • AbbVie
  • Johnson and Johnson
  • Novo Nordisk
  • Amgen
  • Pfizer
  • AstraZeneca
  • Novartis

Group 2: Regional and specialist players

  • Regeneron
  • Sanofi
  • Bristol Myers Squibb
  • Takeda
  • CSL
  • Eli Lilly
  • Biogen
  • UCB
  • Daiichi Sankyo

Group 3: Emerging and niche players

  • Innovent Biologics
  • Akeso
  • Biocon
  • Celltrion
  • Junshi Biosciences

Research methodology

Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the biologics market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.

The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 8.0% is calculated from the resulting values.

The market is divided by product, by therapy area, by molecule type, by manufacturing source, by route of administration. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.

Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.

Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.

Read the full research methodology

Frequently asked questions

How big is the biologics market?

The global biologics market is estimated at USD 470 bn in 2025 and USD 508 bn in 2026.

How fast will the biologics market grow?

It is forecast to reach USD 1.1 tn by 2036, a compound annual growth rate of 8.0% from 2026, an increase of USD 588 bn.

Which country is the largest market for biologics?

United States is the largest market by revenue at USD 264 bn in 2026, 52.0% of the global total. The three largest countries together hold 64.0%.

Which country is growing fastest?

Among the ten largest markets, China is growing fastest at 12.1% a year from 2026 to 2036.

Which biologics segment is largest?

In the by product split, Monoclonal antibodies is the largest segment with 55.0% of 2026 revenue.

Who are the leading biologics companies?

Global leaders include Roche, Merck, AbbVie, Johnson and Johnson.

Need the full report?

Request a sample to see the structure, tables and country detail.

Request a free sample

Related markets in Healthcare

← Biobanking Biomarker Discovery →

All Healthcare markets →

Request a sample